UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
|
|
Date of Report (Date of Earliest Event Reported): |
|
August 29, 2006 (August 28, 2006) |
Endo Pharmaceuticals Holdings Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-15989 |
|
13-4022871 |
|
_____________________ |
|
_____________ |
|
______________ |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
|
|
|
|
|
|
|
100 Endo Boulevard, Chadds Ford, PA |
|
|
|
19317 |
|
_________________________________ |
|
|
|
___________ |
|
|
|
|
|
Registrant’s telephone number, including area code |
|
(610) 558-9800 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On August 28, 2006, the Company entered into an agreement with The Purdue Frederick Company and related companies (Purdue Frederick) providing for a complete settlement of Civil Action Nos. 00 Civ. 8029, 01 Civ. 2109, and 01 Civ. 8177 (SHS) (S.D.N.Y.) (Purdue Litigation) concerning the validity and enforceability of U.S. Patent Nos. 5,549,912, 5,508,042 and 5,656,295 relating to OxyContin (the Purdue Patents), as well as the alleged infringement by the Company and its subsidiary, Endo Pharmaceuticals Inc. (EPI), of the Purdue Patents. A copy of the settlement agreement, including all exhibits thereto, and the Company's press release issued on August 28, 2006 regarding this settlement, are attached hereto as Exhibits 99.1 and 99.2, respectively, both of which are hereby incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
|
(d) |
Exhibits. |
|
Exhibit Number |
Description |
|
99.1 |
Settlement Agreement, dated as of August 28, 2006, by and among Purdue Pharma L.P., The Purdue Frederick Company Inc. d/b/a/ The Purdue Frederick Company, The P.F. Laboratories, Inc., Euro-Celtique S.A., Endo Pharmaceuticals Inc. and Endo Pharmaceuticals Holdings Inc. |
|
99.2 |
Press Release of Endo Pharmaceuticals Holdings Inc. dated August 28, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ENDO PHARMACEUTICALS HOLDINGS INC.
(Registrant)
|
|
By: |
/s/ CAROLINE B. MANOGUE |
| |||
|
|
Name: |
Caroline B. Manogue |
| |||
|
|
Title: |
Executive Vice President, Chief Legal Officer & Secretary | ||||
Dated: August 29, 2006
INDEX TO EXHIBITS
|
Exhibit No. |
Description |
|
99.1 |
Settlement Agreement, dated as of August 28, 2006, by and among Purdue Pharma L.P., The Purdue Frederick Company Inc. d/b/a/ The Purdue Frederick Company, The P.F. Laboratories, Inc., Euro-Celtique S.A., Endo Pharmaceuticals Inc. and Endo Pharmaceuticals Holdings Inc. |
|
99.2 |
Press Release of Endo Pharmaceuticals Holdings Inc. dated August 28, 2006. |